- |||||||||| enuzovimab (HFB30132A) / HiFiBiO, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Pharmsynthez
Clinical, P1 data, PK/PD data, Journal: Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study. (Pubmed Central) - Jun 19, 2023
P1
Our data support further clinical development of HFB30132A. Clinical Trial Registration: https://clinicaltrials.gov, identifier: NCT05275660.
- |||||||||| enuzovimab (HFB30132A) / HiFiBiO, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Pharmsynthez
Trial completion, Trial primary completion date: Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults (clinicaltrials.gov) - Mar 11, 2022
P1, N=24, Completed,
Clinical Trial Registration: https://clinicaltrials.gov, identifier: NCT05275660. Active, not recruiting --> Completed | Trial primary completion date: Apr 2021 --> Jul 2021
- |||||||||| enuzovimab (HFB30132A) / HiFiBiO, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Pharmsynthez
Enrollment closed: Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults (clinicaltrials.gov) - Jan 27, 2021
P1, N=24, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Apr 2021 --> Jul 2021 Recruiting --> Active, not recruiting
|
